Drug Insight: aggrecanases as therapeutic targets for osteoarthritis
Amanda J Fosang* and Christopher B Little
Correspondence *University of Melbourne Department of Paediatrics and Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria 3052, Australia
Email amanda.fosang@mcri.edu.au
High concentrations of intact aggrecan are required for effective weight-bearing in healthy cartilage. Aggrecanases from the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) enzyme family, particularly ADAMTS-4 and ADAMTS-5, are thought to be involved in the pathogenesis of osteoarthritis. In this Review, Drs Fosang and Little discuss potential disease-modifying agents for osteoarthritis that could trigger the downregulation of ADAMTS enzymes.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
